Skip to main content

Table 5 Least square mean changes in total cholesterol, high-density lipoprotein cholesterol and triglyceride from baseline after 8 weeks of treatment

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

  Summary of each treatment FMS/RSV vs. FMS FMS/RSV vs. RSV
  FMS/RSV
(N = 46)
FMS
(N = 45)
RSV
(N = 44)
LSM difference (SE) P-valuea LSM difference (SE) P-valuea
Total cholesterol −36.13 (1.77) −3.62 (1.92) −35.99 (1.95) −32.51 (2.44)   −0.14 (2.45)  
 95% CI (−39.63, −32.64) (−7.41, 0.17) (−39.86, −32.13) (−37.34, −27.69) <0.001 (−4.99, 4.71) 0.954
HDL-C 10.24 (2.63) −3.22 (2.86) 13.43 (2.95) 13.47 (3.63)   −3.19 (3.67)  
 95% CI (5.03, 15.45) (−8.88, 2.43) (7.60, 19.26) (6.28, 20.65) <0.001 (−10.46, 4.08) 0.387
Triglyceride −12.78 (5.79) 20.30 (6.27) −13.65 (6.41) −33.08 (7.97)   0.88 (8.06)  
 95%CI (−24.24, −1.32) (7.89, 32.71) (−26.34, −0.96) (−48.86, −17.30) <0.001 (−15.08, 16.83) 0.914
  1. HDL-C high-density lipoprotein cholesterol, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LSM least square mean, SE standard error
  2. aComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status